🔬 These tools include reference materials for adeno-associated viruses and lentiviral vectors, which can be used for assay development and validation.
🧬 They also offer a technology transfer framework for viral vectors and a Flex Platform for cell therapy development.
💪 These solutions accelerate the development of new therapies and ensure consistency and confidence for biopharma companies.
Introduction:
Biopharma companies often rely on contract development and manufacturing organizations (CDMOs) for the production of materials for clinical trials and manufacturing therapies. Charles River Laboratories, a veteran CRO and CDMO, offers a suite of tools and services to support biopharma companies throughout the drug discovery and development process. They have developed reference materials for adeno-associated viruses (AAV) and lentiviral vectors (LVV) to ensure safety and efficacy testing, as well as a framework for technology transfer of viral vectors. Additionally, they have launched the Flex Platform for CAR T and TCR T cells, providing a modular and flexible solution for cell therapy development.
- Charles River Laboratories offers tools and services to support biopharma companies in the production and testing of cell, gene, and gene-modified cell therapy products.
- They have developed reference materials for AAV and LVV to assist with safety and efficacy testing.
- Charles River has launched a framework for technology transfer of viral vectors, facilitating program continuity and de-risking supply chains.
- The company has introduced the Flex Platform for CAR T and TCR T cells, providing a modular and flexible solution for cell therapy development.
- These tools and services aim to accelerate and improve the development of drug therapies and support the growing demand for gene-modified cell therapies.
Conclusion:
Charles River Laboratories offers a comprehensive suite of tools and services to support biopharma companies in the development and manufacturing of cell, gene, and gene-modified cell therapy products. Their reference materials, technology transfer framework, and Flex Platform contribute to the acceleration and improvement of drug therapies, ensuring consistency and confidence for biopharma companies.